nach oben

Erschienen in:

01.06.2012 | Schwerpunkt

Medikamentöse Therapie des Fibromyalgiesyndroms

Systematische Übersicht und Metaanalyse

verfasst von: Prof. Dr. C. Sommer, W. Häuser, R. Alten, F. Petzke, M. Späth, T. Tölle, N. Üçeyler, A. Winkelmann, E. Winter, K.J. Bär

Erschienen in: Der Schmerz | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Die planmäßige Aktualisierung der S3-Leitlinie zum Fibromyalgiesyndrom (FMS; AWMF-Registernummer 041/004) wurde ab März 2011 vorgenommen.

Material und Methoden

Die Leitlinie wurde unter Koordination der Deutschen Interdisziplinären Vereinigung für Schmerztherapie (DIVS) von 9 wissenschaftlichen Fachgesellschaften und 2 Patientenselbsthilfeorganisationen entwickelt. Acht Arbeitsgruppen mit insgesamt 50 Mitgliedern wurden ausgewogen in Bezug auf Geschlecht, medizinischen Versorgungsbereich, potenzielle Interessenkonflikte und hierarchische Position im medizinischen bzw. wissenschaftlichen System besetzt.

Die Literaturrecherche erfolgte über die Datenbanken Medline, PsycInfo, Scopus und Cochrane Library (bis Dezember 2010). Die Graduierung der Evidenzstärke erfolgte nach dem Schema des Oxford Center for Evidence Based Medicine. Grundlage der Empfehlungen waren die Evidenzstärke, die Wirksamkeit (Metaanalyse der Zielvariablen Schmerz, Schlaf, Müdigkeit und gesundheitsbezogene Lebensqualität), die Akzeptanz (Abbruchrate in Studien), Risiken (Nebenwirkungen) und die Anwendbarkeit der Therapieverfahren im deutschen Gesundheitssystem. Die Formulierung und Graduierung der Empfehlungen erfolgte in einem mehrstufigen, formalisierten Konsensusverfahren. Die Leitlinie wurde von den Vorständen der beteiligten Fachgesellschaften begutachtet.

Ergebnisse und Schlussfolgerung

Amitriptylin und – bei komorbiden depressiven Störungen oder generalisierter Angststörung – Duloxetin werden empfohlen. Der Off-label-Gebrauch von Duloxetin oder Pregabalin kann im Falle von fehlenden komorbiden depressiven Störungen oder fehlender generalisierter Angststörung erwogen werden. Starke Opioide werden nicht empfohlen.

Nur mit Berechtigung zugänglich

Anderberg UM, Marteinsdottir I, Knorring L von (2000) Citalopram in patients with fibromyalgia – a randomized, double-blind, placebo-controlled study. Eur J Pain 4:27–35PubMedCrossRef

Andrade C, Sandarsh S, Chethan KB, Nagesh KS (2010) Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry 71:1565–1575

Arnold LM, Hess EV, Hudson JI et al (2002) A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med 112:191–197PubMedCrossRef

Arnold LM, Lu Y, Crofford LJ et al (2004) A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 50:2974–2984PubMedCrossRef

Arnold LM, Rosen A, Pritchett YL et al (2005) A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 119:5–15PubMedCrossRef

Arnold LM, Goldenberg DL, Stanford SB et al (2007) Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum 56:1336–1344PubMedCrossRef

Arnold LM, Russell IJ, Diri EW et al (2008) A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 9:792–805

Arnold LM, Clauw D, Wang F et al (2010a) Flexible dosed duloxetine in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. J Rheumatol 37:2578–2586

Arnold LM, Gendreau RM, Palmer RH et al (2010b) Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 62:2745–2756PubMedCrossRef

10.

Arnold LM, Chatamra K, Hirsch I, Stoker M (2010c) Safety and efficacy of esreboxetine in patients with fibromyalgia: An 8-week, multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 32:1618–1632PubMedCrossRef

11.

Ataoglu S, Ataoglu A, Erdogan F, Sarac J (1997) Comparison of paroxetine, amitriptyline in the treatment of fibromyalgia. Turk J Med Sci 27:535–539

12.

AWMF (o J) Leitlinie Angststörungen. http://www.awmf.org/leitlinien/detail/ll/028-022.html

13.

Azad KAK, Alam MN, Haq SA et al (2000) Vegetarian diet in the treatment of fibromyalgia. Bangladesh Medical Research Council Bulletin 26:41–47PubMed

14.

Bennett RM, Gatter RA, Campbell SM (1988) A comparison of cyclobenzaprine and placebo in the management of fibrositis. A double-blind controlled study. Arthritis Rheum 31:1535–1542PubMedCrossRef

15.

Bennett RM, Clark SC, Walczyk J (1998) A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. Am J Med 104:227–231PubMedCrossRef

16.

Bennett RM, Kamin M, Karim R, Rosenthal N (2003) Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. Am J Med 114:537–545PubMedCrossRef

17.

Bennett RM, Schein J, Kosinski MR et al (2005) Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis Rheum 53:519–527 (Doppelpublikation)PubMedCrossRef

18.

Bessette L, Carette S, Fosse A (1998) A placebo controlled crossover trial of subcutaneous salmon calcitonin in the treatment of patients with fibromyalgia. Scand J Rheumatol 27:112–116PubMedCrossRef

19.

Biasi G, Manca S, Manganelli S, Marcolongo R (1998) Tramadol in the fibromyalgia syndrome: a controlled clinical trial versus placebo. Int J Clin Pharmacol Res 18:13–19 (experimentelle Studie)PubMed

20.

Bibolotti E, Borghi C, Pasculii E et al (1986) The management of fibrositis. A double-blind comparison of maprotiline, chlomipramine and placebo. Clin Trials 23:269–280 (berichtete Endpunkte für Analyse nicht geeignet)

21.

Branco JC, Zachrisson O, Perrot S et al (2010) A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. J Rheumatol 37:851–859

22.

Callejas Rubio JL, Fernández Moyano A, Navarro Hidalgo D, Palmero Palmero C (2003) Percutaneous fentanyl in fibromyalgia. Med Clin (Barc) 120:358–359

23.

Cantini F, Bellandi F, Niccoli L et al (1994) Fluoxetin combined with cyclobenzaprine in the treatment of fibromyalgia. Minerva Med 85:97–100PubMed

24.

Capaci K, Hepgüler S (2002) Comparison of the effects of amitriptyline and paroxetine in the treatment of fibromyalgia syndrome. Pain Clinic 14:223–228CrossRef

25.

Carette S, McCain GA, Bell DA, Fam AG (1986) Evaluation of amitriptyline in primary fibrositis. A double-blind, placebo-controlled study. Arthritis Rheum 29:655–659PubMedCrossRef

26.

Carette S, Bell MJ, Reynolds WJ et al (1994) Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial. Arthritis Rheum 37:32–40PubMedCrossRef

27.

Carette S, Oakson G, Guimont C, Steriade M (1995) Sleep electroencephalography and the clinical response to amitriptyline in patients with fibromyalgia. Arthritis Rheum 38:1211–1217PubMedCrossRef

28.

Caruso I, Sarzi Puttini PC, Boccassini L et al (1987) Double-blind study of dothiepin versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res 15:154–159

29.

Chappell AS, Littlejohn G, Kajdasz DK et al (2009) A 1-year safety and efficacy study of duloxetine in patients with fibromyalgia. Clin J Pain 25:365–375PubMedCrossRef

30.

Chappell AS, Bradley LA, Wiltse C et al (2009) A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. Int J Gen Med 1:91–100PubMed

31.

Clark S, Tindall E, Bennett RM (1985) A double blind crossover trial of prednisone versus placebo in the treatment of fibrositis. J Rheumatol 12:980–983

32.

Clauw DJ, Mease P, Palmer RH et al (2008) Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 30:1988–2004PubMedCrossRef

33.

Crofford LJ, Rowbotham MC, Mease PJ et al (2005) Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52:1264–1273PubMedCrossRef

34.

Crofford LJ, Mease PJ, Simpson SL et al (2008) Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain 136:419–431 (Studiendesign nicht für Metaanalyse geeignet)PubMedCrossRef

35.

Cuatrecasas G, Gonzalez MJ, Alegre C et al (2010) High prevalence of growth hormone deficiency in severe fibromyalgia syndromes. J Clin Endocrinol Metab 95:4331–4337

36.

Deutsche Gesellschaft für Gynäkologie und Geburtshilfe. Hormontherapie (HT) in der Peri- und Postmenopause. http://www.awmf.org/leitlinien/detail/ll/015-062.html

37.

Distler O, Eich W, Dokoupilova E et al (2010) Evaluation of the efficacy and safety of terguride in patients with fibromyalgia syndrome: results of a twelve-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 62:291–300PubMedCrossRef

38.

Drewes HM (1991) Zopiclone in the treatment of sleep abnormalities in fibromyalgia. Scand J Rheumatol 20:288–293PubMedCrossRef

39.

Eksioglu E, Yazar D, Bal A et al (2007) Effects of Stanger bath therapy on fibromyalgia. Clin Rheumatol 26:691–694PubMedCrossRef

40.

Erhan E, Uyar M, Turan et al (2000) Ağrı. Fibromyalji tedavisinde amitriptilin ve fluvoksaminin karşılaştırılması 1:32–36 (türkisch; nur Abstract erhältich; Studienautoren nicht per E-Mail erreichbar)

41.

Färber L, Stratz T, Brückle W et al (2000) Efficacy and tolerability of tropisetron in primary fibromyalgia – a highly selective and competitive 5-HT3 receptor antagonist. German Fibromyalgia Study Group. Scand J Rheumatol Suppl 113:49–54PubMed

42.

Fernández-Rodriguez A, Hernánz-Mediano W, Gutierrez-Rubio A, et al (1996) Comparison of tenoxicam and bromazepan in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain 65:221–225PubMedCrossRef

43.

Finckh A, Berner IC, Aubry-Rozier L (2005) A randomized controlled trial of de-hydroepiandrosterone in postmenopausal women with fibromyalgia. J Rheumatol 32:1336–1340

44.

Fors EA, Sexton H, Gotestam KG (2002) The effect of guided imagery and amitriptyline on daily fibromyalgia pain: a prospective, randomized, controlled trial. J Psychiatr Res 36:179–187 (Kombination AMT mit geleiteter Imagination)

45.

Fosaluzza V, Vita S de (1992) Combined therapy with cyclobenzaprine and ibuprofen in primary fibromyalgia syndrome. Int J Clin Pharm Res 12:99–102

46.

Garcia J, Simon MA, Duran M et al (2006) Differential efficacy of a cognitive-behavioral intervention versus pharmacological treatment in the management of fibromyalgic syndrome. Psychol Health Med 11:498–506PubMedCrossRef

47.

Gendreau RM, Thorn MD, Gendreau JF et al (2005) Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 32:1975–1985

48.

Giordano N, Geraci S, Santacroce C et al (1999) Efficacy and tolerability of paroxetine in patients with fibromyalgia syndrome: a single-blind study. Curr Ther Res 60:696–702 (Endpunktdarstellung nicht verwertbar)CrossRef

49.

Ginsberg F, Mancaux A, Joos E (1996) A randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia. J Musculoskel Pain 4:37–47

50.

Ginsberg F, Joos E, Geczy J et al (1998) A pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia. J Musculoskelet Pain 6:6–17CrossRef

51.

Glaxo Protocol No ROF102100. A randomised, double-blind, placebo controlled, parallel group study to investigate the safty and efficacy of controlled-release ropinirole (CR) (1–24 mg) administered once daily for 12 weeks in subjects with fibromyalgia. http://www.clinicalstudyresults.org/documents/company-study_5744_0.pdf. Zugegriffen: 9. August 2010

52.

Goldenberg DL, Felson DT, Dinerman H (1986) A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum 29:1371–1377PubMedCrossRef

53.

Goldenberg D, Mayskiy M, Mossey C et al (1996) A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 39:1852PubMedCrossRef

54.

González-Viejo MA, Avellanet M, Hernández-Morcuende MI (2005) A comparative study of fibromyalgia treatment: ultrasonography and physiotherapy versus sertraline treatment. Ann Readapt Med Phys 48:610–615 (französisch)PubMedCrossRef

55.

Gronblad M, Nykanen J, Konttinen Y (1993) Effect of zopiclone on sleep quality, morning stiffness, widespread tenderness and pain and general discomfort in primary fibromyalgia patients. A double-blind randomized trial. Clin Rheumatol 12:186–191PubMedCrossRef

56.

Gülec H, Capkin E, Sayar K (2007) The evaluation of the effectiveness of amitriptyline versus venlafaxine in female patients diagnosed with fibromyalgia syndrome. Klinik Psikofarmakoloji Buelteni 17:68–73 (türkisch)

57.

Gür A, Karakoc M, Nas K et al (2002) Effects of low power laser and low dose amitriptyline therapy on clinical symptoms and quality of life in fibromyalgia: a single-blind, placebo-controlled trial. Rheumatol Int 22:188–193PubMedCrossRef

58.

Hamaty D, Valentine JL, Howard R et al (1989) The plasma endorphin, prostaglandin and catecholamine profile of patients with fibrositis treated with cyclobenzaprine and placebo: a 5-month study. J Rheumatol Suppl 19:164–168

59.

Hannonen P, Malminiemi K, Yli-Kerttula U et al (1998) A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder. Br J Rheumtol 37:1279–1286CrossRef

60.

Häuser W, Bernardy K, Uçeyler N, Sommer C (2009) Treatment of fibromyalgia syndrome with gabapentin and pregabalin – a meta-analysis of randomized controlled trials. Pain 145:69–81PubMedCrossRef

61.

Heymann RE, Helfenstein M, Feldman D(2001) A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. An analysis of outcome measures. Clin Exp Rheumatol 19:697–702PubMed

62.

Holman AJ, Myers RR (2005) A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 52:2495–505PubMedCrossRef

63.

Hrycaj P, Stratz T, Mennet P (1996) Pathogenetic aspects of responsiveness to ondansetron (5-hydroxytryptamine type 3 receptor antagonist) in patients with primary fibromyalgia syndrome – a preliminary study. J Rheumatol 23:1418–1423

64.

Hussain SA, Al-Khalifa II, Jasim NA, Gorial FI (2010) Adjuvant use of melatonin for treatment of fibromyalgia. J Pineal Res 50:267–271. DOI: 10.1111/j.1600–079X.2010.00836.x

65.

Isomeri R, Mikkelsson M, Latikka P, Kammonen K (1993) Effects of amitriptyline and cardiovascular fitness training on pain in patients with primary fibromyalgia. J Muscul Pain 1:253–260 (Kombination von AMT mit Stretching)

66.

Jaeschke R, Adachi J, Guyatt G et al (1991) Clinical usefulness of amitriptyline in fibromyalgia: the results of 23 N-of-1 randomized controlled trials. J Rheumatol 18:447–451 (berichtete Endpunkte für Analyse nicht geeignet)

67.

Jang ZY, Li CD, Qiu L et al (2010) Combination of acupuncture, cupping and medicine for treatment of fibromyalgia syndrome: a multi-central randomized controlled trial. Zhongguo Zhen Jiu 30:265–269 (Chinesisch; berichtete Endpunkte laut englischsprachigem Abstract nicht für Analyse geeignet)PubMed

68.

Joshi MN, Joshi R, Jain AP (2009) Affect of amitriptyline vs. physiotherapy in management of fibromyalgia syndrome: what predicts a clinical benefit? J Postgrad Med 55:185–189 (keine Randomisierung)

69.

Kempenaers C, Simenon G, Vander Elst M (1994) Effect of an antidiencephalon immune serum on pain and sleep in primary fibromyalgia. Neuropsychobiology 30:66–72PubMedCrossRef

70.

Kendall SA, Schaadt ML, Graff LB et al (2004) No effect of antiviral (valacyclovir) treatment in fibromyalgia: a double blind, randomized study. J Rheumatol 31:783–784

71.

Lowe JC, Reichman AJ, Yellin BA (1997) The process of change during T3 treatment for euthyroid fibromyalgia: a double-blind placebo-controlled crossover study. Clin Bulletin Myofas Ther 2:91–124CrossRef

72.

Lowe JC, Garrison R, Reichman AJ et al (1997) Effectiveness and safety of T3 (triiodothyronine) therapy for euthyroid fibromyalgia: a double-blind placebo-controlled response-driven crossover study. Clin Bulletin Myofas Ther 2:31–58CrossRef

73.

McCleane G (2000) Does intravenous lidocaine reduce fibromyalgia pain? A randomized, double-blind, placebo controlled cross-over study. Pain Clinic 12:181–185CrossRef

74.

Mease PJ, Russell IJ, Arnold LM et al (2008) A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 35:502–514

75.

Mease PJ, Clauw DJ, Gendreau RM et al (2009) The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. J Rheumatol 36:398–409

76.

Moldofsky H, Lue FA, Mously C (1996) The effect of zolpidem in patients with fibromyalgia: a dose ranging, double blind, placebo controlled, modified crossover study. J Rheumatol 23:529–533

77.

Moldofsky H, Inhaber NH, Guinta DR, Alvarez-Horine SB (2010) Effects of sodium oxybate on sleep physiology and sleep/wake-related symptoms in patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled study. J Rheumatol 37:2156–2166

78.

Müller A, Rempp C, Kopferschmitt J et al (2005) Effects of intravenous ketamine administered for three days in patients with fibromyalgic pain: double-blind, crossover study versus placebo. Douleurs: Evaluation – Diagnostic – Traitement 6:151–159 (französisch)

79.

Musculoskeletal report: Pfizer stops work on esreboxetine for FM. http://www.mskreport.com/articles.cfm?articleID= 3293. Zugegriffen: 15. August 2011

80.

Nørregaard J, Volkmann H, Danneskiold-Samsøe B (1995) A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain 61:445–449PubMedCrossRef

81.

Olin R, Klein R, Berg PA (1998) A randomised double-blind 16-week study of ritanserin in fibromyalgia syndrome: clinical outcome and analysis of autoantibodies to serotonin, gangliosides and phospholipids. Clin Rheumatol 17:89–94PubMedCrossRef

82.

Ozerbil O, Okudan N, Gokbel H, Levendoglu F (2006) Comparison of the effects of two antidepressants on exercise performance of the female patients with fibromyalgia. Clin Rheumatol 25:495–497 (Endpunktdarstellung nicht verwertbar)PubMedCrossRef

83.

Patkar AA, Masand PS, Krulewicz S et al (2007) A randomized, controlled, trial of controlled release paroxetine in fibromyalgia. Am J Med 120:448–454PubMedCrossRef

84.

Pattrick M, Swannell A, Doherty M (1993) Chlormezanone in primary fibromyalgia syndrome: a double blind placebo controlled study. Br J Rheumatol 32:55–58PubMedCrossRef

85.

Pfizer. Protocol No. A0081100: A 14 week, randomized, double-blind, placebo-controlled trial of pregabalin twice daily in patients with fibromyalgia. http://pdf.clinicalstudyresults.org/documents/company-study_4636_0.pdf. Zugegriffen: 31. März 2009

86.

Posner IA (1994) Treatment of fibromyalgia syndrome with intravenous lidocaine: a prospective, randomized pilot study. J Musculoskelet Pain 2:55–65

87.

Puls F, Agne C, Klein F et al (2011) Pathology of flupirtine-induced liver injury: a histological and clinical study of six cases. Virchows Arch 458:709–716PubMedCrossRef

88.

Quijada-Carrera J, Valenzuela-Castaño A et al (1996) Comparison of tenoxicam and bromazepan in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain 65:221–225PubMedCrossRef

89.

Quimby LG, Gratwick GM, Whitney CD (1989) A randomized trial of cyclobenzaprine for the treatment of fibromyalgia. J Rheumatol Suppl 19:140–143

90.

Raphael JH, Southall JL, Kitas GD (2003) Adverse effects of intravenous lignocaine therapy in fibromyalgia syndrome. Rheumatology (Oxford) 42:185–186

91.

Russell IJ, Kamin M, Bennett RM et al (2000) Efficacy of tramadol in treatment of pain in fibromyalgia. J Clin Rheumatol 6:250–257

92.

Russell IJ, Fletcher EM, Michalek JE et al (1991) Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis Rheum 34:552–560PubMedCrossRef

93.

Russell IJ, Michalek JE, Kang YK, Richards AB (1999) Reduction of morning stiffness and improvement in physical function in fibromyalgia syndrome patients treated sublingually with low doses of human interferon-alpha. J Interferon Cytokine Res 19:961–968

94.

Russell IJ, Mease PJ, Smith TR et al (2008) Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 136:432–444PubMedCrossRef

95.

Russell IJ, Perkins AT, Michalek JE et al (2009) Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis Rheum 60:299–309PubMedCrossRef

96.

Sadreddini S, Molaeefard M, Noshad H et al (2008) Efficacy of Raloxifen in treatment of fibromyalgia in menopausal women. Eur J Intern Med 19:350–355PubMedCrossRef

97.

Santandrea S, Montrone F, Sarzi-Puttini P et al (1993) A double-blind crossover study of two cyclobenzaprine regimens in primary fibromyalgia syndrome. J Int Med Res 21:74–80

98.

Scharf MB, Baumann M, Berkowitz DV (2003) The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. J Rheumatol 30:1070–1074

99.

Scudds RA, McCain GA, Rollman GB, Harth M (1989) Improvements in pain responsiveness in patients with fibrositis after successful treatment with amitriptyline. J Rheumatol Suppl 19:98–103

100.

Sencan S, Karan A, Muslumanoglu L et al (2004) A study to compare the therapeutic efficacy of aerobic exercise and paroxetine in fibromyalgia syndrome. J Back Musculoskeletal Rehabil 17:57–61

101.

Skrabek RQ, Galimova L, Ethans K, Perry D (2008) Nabilone for the treatment of pain in fibromyalgia. J Pain 9:164–173

102.

Sommer C, Häuser W, Berliner M et al (2008) Medikamentöse Therapie des Fibromyalgiesyndroms. Schmerz 22:313–323PubMedCrossRef

103.

Sörensen J, Bengtsson A, Ahlner J et al (1997) Fibromyalgia – are there different mechanisms in the processing of pain? A double blind crossover comparison of analgesic drugs. J Rheumatol 24:1615–1621 (experimentelle Studie)

104.

Sörensen J, Bengtsson A, Bäckman E et al (1995) Pain analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocaine, and ketamine. Scand J Rheumatol 24:360–365 (experimentelle Studie)PubMedCrossRef

105.

Späth M, Stratz T, Neeck G et al (2004) Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia. Scand J Rheumatol 33:267–270PubMedCrossRef

106.

Stoll LA (2000) Fibromyalgia symptoms relieved by flupirtine: an open-label case series. Psychosomatics 41:371–372PubMedCrossRef

107.

Targino RA, Imamura M, Kaziyama HH et al (2008) A randomized controlled trial of acupuncture added to usual treatment for fibromyalgia. J Rehabil Med 40:582–588 (Amitriptylin kombiniert mit multimodaler Therapie bzw. Akupunktur)

108.

Tjäderborn M, Jönsson AK, Ahlner J, Hägg S (2009) Tramadol dependence: a survey of spontaneously reported cases in Sweden. Pharmacoepidemiol Drug Saf 18:1192–1198PubMedCrossRef

109.

Ueberall MA, Mueller-Schwefe GH, Terhaag B (2011) Efficacy and tolerability of flupirtine in subacute/chronic musculoskeletal pain – results of a patient level, pooled re-analysis of randomized, double-blind, controlled trials. Int J Clin Pharmacol Ther 49:637–647PubMed

110.

Vaeroy H, Abrahamsen A, Forre O, Kass E (1989) Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp) versus placebo. Clin Rheumatol 8:245–250PubMedCrossRef

111.

Vitton O, Gendreau M, Gendreau J et al (2004) A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol 19(Suppl 1):S27–35PubMedCrossRef

112.

Vlainich R, Issy AM, Gerola LR, Sakata RK (2010) Effect of intravenous lidocaine on manifestations of fibromyalgia. Pain Pract 10:301–305PubMedCrossRef

113.

Ware MA, Fitzcharles MA, Joseph L, Shir Y (2010) The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg 110:604–610PubMedCrossRef

114.

Ware MA, St Arnaud-Trempe E (2010) The abuse potential of the synthetic cannabinoid nabilone. Addiction 105:494–503PubMedCrossRef

115.

Wolfe F, Cathey MA, Hawley DJ (1994) A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol 23:255–259PubMedCrossRef

116.

Wörz R (1991) Flupirtin bei chronischen myofasziellen Schmerzzuständen. Fortschr Med 109:158–160PubMed

117.

Yavuzer G, Küçükdeveci A, Araslı T, Elhan A (1998) Moclobemid treatment in primary fibromyalgia syndrome. Eur J Phys Med Rehabil 8:35–38 (Kombination mit Biofeedback)

118.

Yunus MB, Masi AT, Aldag JC (1989) Short term effects of ibuprofen in primary fibromyalgia syndrome: a double blind, placebo controlled trial. J Rheumatol 16:527–532

Titel: Medikamentöse Therapie des Fibromyalgiesyndroms
Systematische Übersicht und Metaanalyse
verfasst von: Prof. Dr. C. Sommer
W. Häuser
R. Alten
F. Petzke
M. Späth
T. Tölle
N. Üçeyler
A. Winkelmann
E. Winter
K.J. Bär
Publikationsdatum: 01.06.2012
Verlag: Springer-Verlag
Erschienen in: Der Schmerz / Ausgabe 3/2012
Print ISSN: 0932-433X
Elektronische ISSN: 1432-2129
DOI: https://doi.org/10.1007/s00482-012-1172-2

Neu im Fachgebiet AINS

23.04.2024 | Appendizitis | Nachrichten

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren

Springer Medizin

Medikamentöse Therapie des Fibromyalgiesyndroms

Systematische Übersicht und Metaanalyse

Zusammenfassung

Hintergrund

Material und Methoden

Ergebnisse und Schlussfolgerung

Neu im Fachgebiet AINS

Hinter dieser Appendizitis steckte ein Erreger

Ärztliche Empathie hilft gegen Rückenschmerzen

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

S3-Leitlinie zu Pankreaskrebs aktualisiert

Update AINS

Springer Medizin

Zusammenfassung

Hintergrund

Material und Methoden

Ergebnisse und Schlussfolgerung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

Physiotherapie und physikalische Verfahren beim Fibromyalgiesyndrom

Das Fibromyalgiesyndrom

Das Fibromyalgiesyndrom

Definition, Diagnostik und Therapie von chronischen Schmerzen in mehreren Körperregionen und des sogenannten Fibromyalgiesyndroms bei Kindern und Jugendlichen

Leitlinie Fibromyalgiesyndrom

Psychotherapie von Patienten mit Fibromyalgiesyndrom

Neu im Fachgebiet AINS

Hinter dieser Appendizitis steckte ein Erreger

Ärztliche Empathie hilft gegen Rückenschmerzen

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

S3-Leitlinie zu Pankreaskrebs aktualisiert

Update AINS